ASCO GU 2014: Will there be a market for Medivation’s enzalutamide in M0 prostate cancer?
The new race to market in advanced prostate cancer is in the M0 asymptomatic space. Several AR antagonists are competing to run trials here but will they lead to men living longer or not?February 10, 2014
Update on immuno-oncology and biomarkers of response
ASCO GU saw an update on the ipilimumab study in post chemotherapy CRPC. New biomarker data published this week in melanoma may be potentially useful in prostate and other tumour types.February 5, 2014
ASCO GU 2014 Optimal targeting of anti PD-1 and PD-L1 therapies in renal cancer
Update on progress with anti-PD1 and PD-L1 immunotherapies in renal cell cancer. Where is the field going in this space?February 4, 2014
ASCO GU 2014 Beyond Enzalutamide and Abiraterone – What’s Next?
Cross resistance between enzalutamide and abiraterone means that new prostate cancer drugs and targets are needed.January 31, 2014
ASCO GU 2014: Will Galeterone make it to market in Prostate Cancer?
At ASCO GU 2014 Tokai Pharmaceuticals report data for the ARMOR2 trial with reformulated galeterone (TOK-001) in men with prostate cancer. Is this drug likely to make it to market?January 30, 2014
ASCO GU Interview with Dr Tom Beer on Medivation PREVAIL trial data
Enzalutamide significantly decreases the risk of death and delays progression in the PREVAIL trialJanuary 28, 2014
ASCO GU 2014: Why does the Medivation PREVAIL trial matter?
At ASCO GU this week, the clinical data will be presented for the Medivation/Astellas PREVAIL phase III clinical trial of enzalutamide (Xtandi) in men with advanced prostate cancer prior to chemotherapy. The results of this trial not only have important commercial implications for Medivation/Astellas but for competitors in the prostate cancer market.January 27, 2014
ASCO GI Keynote: The future of Immunotherapy is Combinations
“We are at beginning of a REVOLUTION in immunotherapy,” said Elizabeth M. Jaffee, MD at the start of American Society of Clinical Oncology GastroIntestinal (ASCO GI) symposium keynote lecture on Immunologic Treatments for GI Cancers.January 21, 2014
Will Exelixis Cabozantinib COMET-1 prostate cancer trial be positive?
The share price of Exelixis ($EXEL) is starting a run-up (after months in the doldrums) in advance of anticipated results from the COMET-1 phase 3 trial in metastatic castrate resistant prostate cancer (mCRPC) for cabozantinib (Cometriq, formerly XL184). Cabozantinib has been shown to significantly improve bone scans and decrease pain, but will it show an improvement in OS?January 6, 2014
ASCO GI 2014 Preview: Pancreatic and Gastric Cancer
Preview of some of the key data being presented at ASCO GI in San Francisco this month.January 3, 2014
ASCO GU 2014 Prostate Cancer Preview #GU14
ASCO GU symposium takes place at the San Francisco Marriott Marquis from Jan 20 – February 1, 2014. This preview discusses data to be presented on enzalutamide (Xtandi), abiraterone (Zytiga), ODM-201, ARN-509, ipilimumab (Yervoy).December 30, 2013